No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CYCN Cyclerion Therapeutics
- 2.7156
- +0.6056+28.70%
Close Jun 14 16:00 ET
- 2.9700
- +0.2544+9.37%
Post 19:09 ET
7.36MMarket Cap8.23P/E (TTM)
2.9699High2.4200Low6.87KVolume2.4500Open2.1100Pre Close18.51KTurnover0.54%Turnover RatioLossP/E (Static)2.71MShares5.250052wk High0.74P/B3.49MFloat Cap1.750152wk Low--Dividend TTM1.29MShs Float420.0000Historical High--Div YieldTTM26.06%Amplitude1.7500Historical Low2.6920Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersIGM Biosciences (NASDAQ:IGMS) shares increased by 36.6% to $11.49 during Wednesday's regular session. The market value of their outstanding shares is at $678.1 million. Akso Health Group (NASDA
Cyclerion Therapeutics | 10-Q: Quarterly report
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersAtreca (NASDAQ:BCEL) shares increased by 102.7% to $0.22 during Thursday's regular session. The company's market cap stands at $8.6 million. Sagimet Biosciences (NASDAQ:SGMT) stock rose 36.13%
Cyclerion Therapeutics Announced That Regina Graul Has Joined The Company As President, Effective Immediately, Peter Hecht Will Continue To Work As A Strategic Consultant And Board Member; Steps Down From CEO Role
Cyclerion Therapeutics Announced That Regina Graul Has Joined The Company As President, Effective Immediately, Peter Hecht Will Continue To Work As A Strategic Consultant And Board Member; Steps Down
Cyclerion Therapeutics Names Regina Graul President >CYCN
Cyclerion Therapeutics Names Regina Graul President >CYCN
Press Release: Cyclerion Appoints Regina Graul, Ph.D., as President
Cyclerion Appoints Regina Graul, Ph.D., as President -- Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep ex
Comments
Dr. Hecht is optimistic about Cyclerion's future under Dr. Graul's leadership, praising her ability and strategic approach. Dr. Graul emphasizes innovative strategies and addressing unmet patient needs for Cyclerion's success.
$Ambipar Emergency Response(AMBI.US$
$ZyVersa Therapeutics(ZVSA.US$
$Top KingWin(TCJH.US$ Look for a pullback to around $5.20 before another new high.
For Monday: $Hesai(HSAI.US$ Breakout is at 10.34.
Still holding: $Cyclerion Therapeutics(CYCN.US$ Broke resistance. Next move will be to 7.00. Still is in uptrend if it stays above 5.01. Last week was its highest volume week in over a year.Short percentage is at 20%. Short interest rate doubled Friday.
$ZyVersa Therapeutics(ZVSA.US$
$Top KingWin(TCJH.US$ Look for a pullback to around $5.20 before another new high.
For Monday: $Hesai(HSAI.US$ Breakout is at 10.34.
Still holding: $Cyclerion Therapeutics(CYCN.US$ Broke resistance. Next move will be to 7.00. Still is in uptrend if it stays above 5.01. Last week was its highest volume week in over a year.Short percentage is at 20%. Short interest rate doubled Friday.
7
18
$Cyclerion Therapeutics(CYCN.US$ in here 6.03 looking ti load if dio more monday
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
